Evaluating the Safety of Maribavir for the Treatment of Cytomegalovirus.

ABSTRACT:

Purpose of review

Cytomegalovirus (CMV) infections are a common complication in solid organ (SOT) and hematopoietic stem cell transplant (HSCT) recipients, leading to increased morbidity and mortality. Currently available treatment options have reduced the burden of infection, but utilization of these agents can be limited by toxicities such as nephrotoxicity and/or myelosuppression as well as emergence of resistance. The expansion of our current armamentarium towards CMV infection is crucial. Here, we review an emerging therapy, maribavir, and the safety and efficacy of this potential new agent for the prophylaxis and treatment of CMV infections including resistant/refractory disease.

Recent findings

Maribavir is a novel agent with CMV activity approved by Federal Food and

SUBMITTER: Gandhi RG 

PROVIDER: S-EPMC8926008 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature